New Candidates for Furin Inhibition as Probable Treat for COVID-19: Docking Output
Furin is a serine protease that takes part in the processing and activation of the host cell pre-proteins. The enzyme also plays an important role in the activation of several viruses like the newly emerging SARS-CoV-2 virus that causes COVID-19 disease with a high rate of virulence and mortality. Unlike viral enzymes, furin owns a constant sequence and active site characteristics and seems to be a better target for drug design for COVID-19 treatment. Considering furin active site as receptor and some approved drugs from different classes including antiviral, antibiotics, and anti protozoa/anti parasites with suspected beneficial effects on COVID-19, as ligands we have carried out docking experiments in HEX software to pickup those capable to bind furin active site with high affinity and suggest them as probable candidates for clinical trials assessments. Our docking experiments show that saquinavir, nelfinavir, and atazanavir with cumulative inhibitory effects of 2.52, 2.16, and 2.13 respectively seem to be the best candidates for furin inhibition even in severe cases of COVID-19 as adjuvant therapy, while clarithromycin, niclosamide, and erythromycin with cumulative inhibitory indices of 1.97, 1.90, and 1.84 respectively with lower side effects than antiviral drugs could be suggested as prophylaxes for the first stage of COVID-19 as a promising treat..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
arXiv.org - (2021) vom: 27. Juli Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dayer, Mohammad Reza [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
XAR032273339 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XAR032273339 | ||
| 003 | DE-627 | ||
| 005 | 20230429064437.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210728s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)XAR032273339 | ||
| 035 | |a (arXiv)2107.12799 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Dayer, Mohammad Reza |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New Candidates for Furin Inhibition as Probable Treat for COVID-19: Docking Output |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Furin is a serine protease that takes part in the processing and activation of the host cell pre-proteins. The enzyme also plays an important role in the activation of several viruses like the newly emerging SARS-CoV-2 virus that causes COVID-19 disease with a high rate of virulence and mortality. Unlike viral enzymes, furin owns a constant sequence and active site characteristics and seems to be a better target for drug design for COVID-19 treatment. Considering furin active site as receptor and some approved drugs from different classes including antiviral, antibiotics, and anti protozoa/anti parasites with suspected beneficial effects on COVID-19, as ligands we have carried out docking experiments in HEX software to pickup those capable to bind furin active site with high affinity and suggest them as probable candidates for clinical trials assessments. Our docking experiments show that saquinavir, nelfinavir, and atazanavir with cumulative inhibitory effects of 2.52, 2.16, and 2.13 respectively seem to be the best candidates for furin inhibition even in severe cases of COVID-19 as adjuvant therapy, while clarithromycin, niclosamide, and erythromycin with cumulative inhibitory indices of 1.97, 1.90, and 1.84 respectively with lower side effects than antiviral drugs could be suggested as prophylaxes for the first stage of COVID-19 as a promising treat. | ||
| 773 | 0 | 8 | |i Enthalten in |t arXiv.org |g (2021) vom: 27. Juli |
| 773 | 1 | 8 | |g year:2021 |g day:27 |g month:07 |
| 856 | 4 | 0 | |u https://arxiv.org/abs/2107.12799 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XAR | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 27 |c 07 | ||
| 953 | |2 045F |a 570 | ||